FDA timeline
FDA’s 2023 safety-risk listing still stands. The 2026 committee vote is a recommendation only, and any change requires FDA rulemaking.
FDA places BPC-157 among bulk drug substances for compounding that may present significant safety risks, citing possible immune reactions, peptide impurities and limited safety information.1
FDA’s Pharmacy Compounding Advisory Committee votes 8 to 6, with one abstention, to recommend adding BPC-157 to the list of substances compounding pharmacies may use. FDA’s own review staff had recommended against it.2,3
The vote is advisory. Rulemaking has not been completed, and BPC-157 remains unapproved.2,3
Sport and military
WADA · S0
Prohibited at all times
The World Anti-Doping Agency lists BPC-157 under S0, non-approved substances, prohibited in and out of competition.4
U.S. Department of Defense
Prohibited for service members
Operation Supplement Safety lists BPC-157 as a prohibited peptide and an unapproved drug found in some wellness products.5
What “research use only” means
“Research use only” is a label for materials intended for laboratory work. It is not an FDA approval, and it does not make a product a drug, a dietary supplement or suitable for human use.
This page is general information, not legal advice. Rules can change; check FDA’s current guidance before relying on it.
Sources
- U.S. Food and Drug Administration. Certain bulk drug substances for use in compounding that may present significant safety risks. fda.gov
- U.S. Food and Drug Administration. July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. fda.gov
- The Hill. FDA panel votes to add peptides to permitted compounding list despite opposition from agency scientists. July 2026. thehill.com
- World Anti-Doping Agency. The Prohibited List. wada-ama.org
- Operation Supplement Safety (U.S. Department of Defense). BPC-157: A prohibited peptide and an unapproved drug found in health and wellness products. opss.org